Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Advanced Proteome Therapeutics Corporation V.APC.H

Alternate Symbol(s):  APTCF

Healthcare Biotechnology
Advanced Proteome Therapeutics Corporation is actively seeking additional funds to advance its core technologies for partnering and other potential revenue streams. It is not engaged in any activity.


TSXV:APC.H - Post by User

Advanced Proteome Therapeutics Corporation
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(27)
•••
Post by Goldnboy1on Feb 05, 2022 1:31am
308 Views
Post# 34400437

News! Clinicals in 2022!

News! Clinicals in 2022!

Animal studies in spring, with expectation of using results to leap into clinicals!

News says they continue to speak to potential licensees!

At this market cap the re rate will be rapid if the right deal done.

Remember historically pre roll back this often traded at $40-$60m market cap. Wouldn't be easy to return there if we are pushing forward on clincals.

Management has eyes on a few drugs that failed in Stage 3. Could be a chance $APC's patents could revive study of these failed drugs. Majority fail for off target toxicity. Which is our strength at preventing.

Stay tuned! 


Miner maybe you should average down. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities